These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34298591)

  • 1. Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg).
    Ramos CO; Canton APM; Seraphim CE; Faria AG; Tinano FR; Mendonca BB; Latronico AC; Brito VN
    J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1371-1377. PubMed ID: 34298591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes of Patients with Central Precocious Puberty due to Hypothalamic Hamartoma after GnRHa Treatment: Anthropometric, Metabolic, and Reproductive Aspects.
    Ramos CO; Latronico AC; Cukier P; Macedo DB; Bessa DS; Cunha-Silva M; Arnhold IJ; Mendonca BB; Brito VN
    Neuroendocrinology; 2018; 106(3):203-210. PubMed ID: 28558376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty.
    Lee HS; Yoon JS; Park KJ; Hwang JS
    PLoS One; 2018; 13(8):e0201906. PubMed ID: 30133462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment.
    Poomthavorn P; Suphasit R; Mahachoklertwattana P
    Gynecol Endocrinol; 2011 Aug; 27(8):524-8. PubMed ID: 21501002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Patients with Central Precocious Puberty Due to Loss-of-Function Mutations in the MKRN3 Gene after Treatment with Gonadotropin-Releasing Hormone Analog.
    Ramos CO; Macedo DB; Canton APM; Cunha-Silva M; Antonini SRR; Stecchini MF; Seraphim CE; Rodrigues T; Mendonca BB; Latronico AC; Brito VN
    Neuroendocrinology; 2020; 110(7-8):705-713. PubMed ID: 31671431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal assessment of auxological parameters, adult height outcome and its determinants in leuprolide-treated Indian girls with idiopathic central precocious puberty.
    Mondkar S; Khadilkar V; Yewale S; Dange N; More C; Khadilkar A
    J Pediatr Endocrinol Metab; 2024 Jan; 37(1):62-68. PubMed ID: 38008794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
    Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty.
    Tanaka T; Niimi H; Matsuo N; Fujieda K; Tachibana K; Ohyama K; Satoh M; Kugu K
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1371-6. PubMed ID: 15598675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
    Massart F; Federico G; Harrell JC; Saggese G
    Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
    Pasquino AM; Pucarelli I; Accardo F; Demiraj V; Segni M; Di Nardo R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty.
    Shim YS; Lim KI; Lee HS; Hwang JS
    PLoS One; 2020; 15(12):e0243212. PubMed ID: 33301485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.
    Pucarelli I; Segni M; Ortore M; Arcadi E; Pasquino AM
    J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1005-10. PubMed ID: 14513877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs.
    Brito VN; Latronico AC; Cukier P; Teles MG; Silveira LF; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2662-9. PubMed ID: 18460564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of gonadotropin-releasing analog treatment for children with central precocious puberty: 15-year experience in southern Thailand.
    Jaruratanasirikul S; Thaiwong M
    J Pediatr Endocrinol Metab; 2011; 24(7-8):519-23. PubMed ID: 21932591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty.
    Leschek EW; Flor AC; Bryant JC; Jones JV; Barnes KM; Cutler GB
    J Pediatr; 2017 Nov; 190():229-235. PubMed ID: 29144249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of leuprorelin 3-month depot (11.25 mg) for idiopathic central precocious puberty treatment of Chinese girls: a single-center retrospective study.
    Huang S; Zhang L; Gao C; Ou H; Hou L; Liu Z; Wang D; Xu Y; Liang L; Meng Z
    J Pediatr Endocrinol Metab; 2024 Jan; 37(1):15-20. PubMed ID: 37975727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty.
    Pasquino AM; Municchi G; Pucarelli I; Segni M; Mancini MA; Troiani S
    J Clin Endocrinol Metab; 1996 Mar; 81(3):948-51. PubMed ID: 8772556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.